上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 论著（公共卫生） • 上一篇    下一篇

使用伊马替尼治疗的慢性粒细胞白血病患者的生命质量影响因素分析

马永华，张开金，刘桂圆，余有任   

  1. 东南大学 公共卫生学院， 南京 210009
  • 出版日期:2016-07-28 发布日期:2016-08-31
  • 通讯作者: 张开金, 电子信箱: njkjzh@163.com。
  • 作者简介:马永华（1990—）， 女， 硕士生; 电子信箱: mayonghua1226@163.com。
  • 基金资助:

    国家自然科学基金 （70973018）；江苏省医疗保险研究会社会招标科研课题（JSYB2014001）

Analysis of factors influencing the quality of life in patients with chronic myeloid leukemia receiving imatinib mesylate treatment

MA Yong-hua, ZHANG Kai-jin, LIU Gui-yuan, YU You-ren   

  1. School of Public Health, Southeast University, Nanjing 210009, China
  • Online:2016-07-28 Published:2016-08-31
  • Supported by:

    National Natural Science Foundation of China, 70973018； Social Research Bidding Projects of Jiangsu Province Medical Insurance Research Council， JSYB2014001

PDF (PC)

778

摘要：

目的 评价使用伊马替尼治疗的慢性粒细胞白血病患者的生命质量，并探讨其影响因素。方法 采用癌症治疗方法功能评估表中文版（FACT-BRM）对江苏省144例使用伊马替尼治疗的慢性粒细胞白血病患者进行调查。从一般人口学特征角度，采用方差分析探讨各因素对生命质量的影响，并运用多元线性回归分析探讨各因素对治疗效果的影响。结果 慢性粒细胞白血病患者生命质量总分为 99.08±20.91，生理状况、社会/家庭状况、情感状况、功能状况、附加关注生理维度和附加关注心理维度得分分别为 19.52±5.36、16.37±6.72、15.89±4.72、13.08±6.18、18.98±4.63和15.24±4.28。多元线性回归分析显示： 年龄、文化程度、经济状况和医保类型是影响患者生命质量的主要因素。结论 慢性粒细胞白血病患者的生命质量较差;生命质量应成为伊马替尼治疗慢性粒细胞白血病临床疗效评价指标之一。

关键词: 伊马替尼, 慢性粒细胞白血病, 生命质量, 影响因素分析

Abstract:

Objective To evaluate the quality of life (QOL) in patients with chronic myeloid leukemia (CML) receiving the imatinib mesylate treatment and explore relevant influencing factors. Methods Functional assessment of cancer therapy generic scale (FACT-BRM) was used to survey 144 patients with CML receiving the imatinib mesylate treatment in Jiangsu Province. The effects of relevant factors on QOL were processed with the variance analysis from the perspective of general demographic characteristics. The effects of relevant factors on the efficacy were explored with the multiple linear regression analysis. Results The total QOL score of patient with CML was 99.08±20.91. Scores of dimensions, i.e. physiological status, social/family status, emotional status, functional status, additional physiological status, and additional emotional status, were 19.52±5.36, 16.37±6.72, 15.89±4.72, 13.08±6.18, 18.98±4.63, and 15.24±4.28, respectively. The multivariate linear regression analysis indicated that age, education level, income, and type of medical insurance were major factors influencing the patients QOL. Conclusion The QOL in patient with CML was poor. QOL should be considered as an index for assessing the clinical efficacy of imatinib mesylate for the treatment of CML.

Key words: imatinib mesylate, chronic myeloid leukemia, quality of life, root case analysis